NEW YORK (GenomeWeb) – Myriad Genetics sued Pathway Genomics on June 13 for infringement of its patent claims underlying BRCA1 and BRCA2 genetic testing.

San Diego-based Pathway issued a statement today stating that it will "vigorously defend" itself against that suit. The legal challenge was spurred by Pathway's launch earlier this month of a next-generation sequencing test for gauging alterations in BRCA1 and BRCA2 genes, called BRCATrue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.